BB-025 Archives - NeuroNews International

Basking doses first patients in phase-one study of stroke drug reversal...

20 November 2025

Basking Biosciences has announced that the first participants have been dosed in a phase-one clinical study of BB-025—a rapid-acting reversal agent designed to specifically...

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Tag: BB-025

Basking doses first patients in phase-one study of stroke drug reversal...